Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Isolated data on the optimized group

<< Previous

Bullboard Posts

Next >>

Comment by fredgoodwinsonon Aug 12, 2022 4:19am

269 Views

Post# 34890602

RE:RE:RE:RE:RE:RE:RE:RE:RE:Isolated data on the optimized group

Interesting topic - so cancer cells that have received an exceptional but not overwhelming dose of ROS can thereby be primed to be more resistant to subsequent exposure - something in the nature of a vaccine?

Guess that the population of this Trial is unlikely to represent more than a very limited opportunity for such undesirable phenotypes to spread or evolve but does it perhaps illustrate a potential for the as-yet entirely unexplained under-dosing of those first 12 to have been damaging even beyond the immediate disaster that it so nearly represented to the Trial and the Company?

<< Previous

Bullboard Posts

Next >>

Drilling company poised to capitalize on market conditions